Affini-T Therapeutics, Inc.

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations	Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Recruiting	Phase 1	2026-07-06		NCT06043713
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Syndactyly, Type I, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 1 / Phase 2	2025-07-30		NCT06105021

Clinical trials